Latest BioAlps news
News
Nagi Bioscience and InVirtuoLabs join forces to bring whole-organism biology into AI drug discovery
Nagi Bioscience, an EPFL spin-off based at EPFL Innovation Park, has announced a new partnership with InVirtuoLabs, based in Ticino,…
News
Distalmotion Secures Up to $70 Million Term Loan to Accelerate US Expansion
Distalmotion, a global MedTech company based à Biopôle-Lausanne and focused on expanding access to robotic surgery in outpatient settings, announced…
News
Neurosterix announces the success of a Phase I trial for NTX-253
The drug candidate, intended for the treatment of schizophrenia, is now set to enter Phase II. Addex holds a 20…
News
Biodelphis Therapeutics, PolaSight and Swiss Soil each receive a Tech Seed loan
The Foundation for Innovation and Technology (FIT) is supporting three life sciences start-ups through Tech Seed loans. Biodelphis Therapeutics is…
News
BioAlps Networking Day – Meet the Exhibitors
About fifteen exhibitors will be waiting for you at the BioAlps Networking Day on 19 November 2026 at Beaulieu Lausanne….
News
Release Therapeutics Secures Non-Dilutive Innosuisse Funding
Release Therapeutics, a privately held Swiss BioMedTech company based at Campus Biotech in Geneva, announced that it has been awarded…
News
Cinainu Receives FDA Breakthrough Therapy Designation for Alopecia Areata
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to CINAINU® (LH-8), an investigational topical treatment for…
News
HUG Climbs to No. 1 in Switzerland in Newsweek’s Smart Hospitals Ranking
Geneva University Hospitals (HUG) are now Switzerland’s most advances hospital in the digital field. In the 2027 edition of Newsweek…
News
FIF Supports Promising Life Sciences Projects
dEEGtal, S-SENTIA and Juturna Bio are the latest projects to receive funding from the FIF, the Canton of Geneva’s innovation…
News
Alcon acquires Neurotech and the only approved treatment for MacTel type 2
Geneva-based eye care leader Alcon has acquired Neurotech Pharmaceuticals, a private biotech company developing therapies for chronic eye diseases, for…
News
Orbis Medicines Enters Multi-Target Drug Discovery Partnership with Novo Nordisk Worth up to USD 1.4 Billion
Orbis Medicines Signs Drug Discovery Deal with Novo Nordisk Worth Up to USD 1.4 billion Orbis Medicines, a biotech company…
News
Three Swiss Health Valley Projects Supported by the EPFL Startup Launchpad
MazeBio, Akteon and HelixScreen are supported by the EPFL Startup Launchpad and taking the next steps towards bringing their technologies to…











